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Abstract: For many decades, we have relied on immortalised retinal cell lines, histology 
of enucleated human eyes, animal models, clinical observation, genetic studies and human 
clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment 
options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for 
deriving retinal lineages has added a powerful alternative tool for discovering new  
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disease-causing mutations, studying genotype-phenotype relationships, performing 
therapeutics-toxicity screening and developing personalised cell therapy. This review 
article provides a clinical perspective on the current and potential benefits of iPSC for 
managing the most common blinding diseases of the eye: inherited retinal diseases and 
age-related macular degeneration. 
Keywords: age-related macular degeneration; inherited retinal disease; retinal dystrophy; 
macular dystrophy; retina; induced pluripotent; stem cells; cell transplantation;  
disease modelling; genetic diagnosis 
 
1. Introduction 
The ability to convert a differentiated somatic cell from a patient into a pluripotent stem cell has 
provided new tools for studying organ development and genotype-phenotype relationships.  
Three-dimensional tissue structures and cells derived from these induced pluripotent stem cells 
(iPSCs) are now being used to screen and test the therapeutic and toxic effects of potential 
pharmacologic agents and gene therapies. More importantly, iPSCs could also be used to provide an 
easily accessible source of tissue for autologous cellular therapy. To date, the greatest potential benefit 
of iPSC technology is in the treatment of retinal diseases. 
The retina is a complex neurovascular tissue within the eye. It contains a network of neurons 
nourished by the retinal and choroidal circulations. Specialised neuronal cells, called rod and cone 
photoreceptors, capture light that enters into the eye. Through phototransduction within the 
photoreceptors and downstream neural processing by the bipolar, amacrine, horizontal and ganglion 
cells within the retina, light signals are transmitted to the primary and secondary visual cortex of the 
brain to enable visual sensation. The functions of these specialised neuronal cells are supported by the 
Muller glial cells and the retinal pigment epithelium (RPE). The ease of visualising retinal neurons and 
assessing the structure-function correlation in detail using readily available imaging devices will 
facilitate the in vivo clinical translation of iPSC technology in the diagnosis and treatment of retinal 
diseases (Figure 1). 
Among hundreds of human retinal diseases, the most significant are age-related macular 
degeneration (AMD) and the inherited retinal diseases (IRDs). Both AMD and IRDs are neither 
preventable nor curable, and they remain the most significant causes of irreversible blindness. The 
underlying processes leading to retinal cell death range from cell-autonomous mechanisms related to 
single gene mutations to complex gene-metabolic-environment interaction, resulting in extracellular 
remodelling, abnormal angiogenesis, chronic inflammation, defective lipid metabolism and oxidative 
injury, as proposed in AMD [1]. The discovery of the pathological basis of these diseases was made 
possible through clinical observation using detailed retinal imaging techniques, human genetic studies, 
histology of post-mortem, enucleated or aborted foetal eyes, immortalised cell line culture systems and 
animal models of retinal diseases. However, in routine clinical practice, retinal diagnosis is rarely 
based on retinal histology because of the significant morbidity associated with retinal biopsy and the 
ease in making a diagnosis, because the retina is easily visualised. The availability of iPSC technology 
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provides an opportunity to obtain retinal tissue without retinal biopsy. There are now several examples 
in which iPSC-derived retinal cells are used to confirm the clinical and genetic diagnosis of  
IRDs [2,3], understand the molecular mechanisms of developmental anomalies of the eye [4] and 
explore the cellular mechanisms of specific genetic mutations [5–8]. In addition to improving 
diagnostic capability, the use of iPSCs in clinical practice could also lead to new treatments for retinal 
diseases (Figure 2). 
Figure 1. An example of high-resolution retinal images from a patient with 
hydroxychloroquine toxicity. (A) Wide-field colour photography; (B) Zoomed-in colour 
image highlighted by the yellow box in (A) of the macular region showing no obvious 
abnormality; (C) Near-infrared reflectance image of the macula showing no obvious 
abnormality; (D) Adaptive optics retinal image highlighted by the yellow box in (C) 
showing the loss of wave-guiding cone outer segments in the perifoveal region; (E) 
Microperimetry showing reduced sensitivity to light in the macular region; (F) Zoomed-in 
image of the perifoveal region showing reduced sensitivity (<25 dB is abnormal); (G) 
Corresponding optical coherence tomography through the fovea showing no obvious loss 
of the ellipsoid zone of the photoreceptors (yellow arrow). 
 
Central to most blinding retinal diseases is the loss of cone photoreceptors. Strategies to preserve or 
replace cone cells are under intense investigation. Cones can be preserved by: (1) anti-oxidant therapy; 
(2) pharmacological therapy that provides neuroprotection; (3) gene correction therapy; and  
(4) cell-based therapy to provide support to cone cells (e.g., RPE or rod cell transplantation). Lost cone 
cells can be replaced by: (1) transplantation of patient-specific or allogeneic photoreceptor precursors 
(along with supporting cells); (2) recruitment of endogenous cells to differentiate into new 
photoreceptor or to become light-responsive cells (optogenetics); or (3) implantation of epi-retinal, 
sub-retinal, suprachoroidal or optic nerve visual prostheses [9–11]. Some of these treatment modalities 
have been investigated in cell culture systems and animal models, and many of these have also been 
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tested in phase I/II clinical trials [12–15]. A major limitation of clinical therapeutics trial in IRDs is the 
vast heterogeneity of the underlying genetic mutation. Many of the approaches to preserve cones may 
only be suitable for one genetic variant, but not another, despite a similar clinical phenotype. Given the 
rarity of many IRDs, randomised clinical trials are not feasible. As an alternative, iPSC-derived retinal 
tissue from many patients with IRDs can now be tested in vitro, simultaneously, in a pre-clinical study, 
for the potential dose-therapeutic effect response and toxicity of various pharmacologic agents or gene 
therapies. As genomic editing techniques are emerging and iPSCs are being used as a cell source for 
replacing lost retinal cells, we now also have the capability of eliminating specific mutations prior to 
retinal differentiation, thus providing the option of autologous transplantation even to patients with  
IRDs [16]. 
Figure 2. A somatic cell from the patient is used to derive induced pluripotent stem cells 
(iPSCs). The iPSC colonies are characterised to ensure pluripotency markers are present, 
they form teratoma or embryoid body and they have stable chromosomes. It may take up to 
three months to derive and validate iPSC lines. The validated iPSC colonies are 
differentiated to form optic vesicle structures, which contain retinal pigment epithelium 
and neural retinal cells. Mature retinal cells can be used for confirming the pathogenicity 
of newly-discovered genetic variants, modelling of developmental or degenerative retinal 
disease, testing of pharmacologic agents or gene therapy and autologous cellular therapy. 
 
There are several excellent reviews on the use of human iPSCs in the study of retinogenesis, 
modelling retinal disease, screening of therapeutics and cell replacement therapy in both AMD and  
IRDs [17–22]. The purpose of this review is to provide an update, from a clinical perspective, on the 
potential for using iPSC technology in routine clinical care of patients with retinal diseases. It will 
expand on clinically relevant issues related to laboratory techniques to derive clinical grade  
iPSC-retina and illustrate examples in which iPSC technology has translated into patient care. 
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2. Derivation of Patient-Specific Retinal Cells from iPSC for Clinical Use 
The availability of human retinal tissue and pure populations of specific types of retinal cells is 
critical to our ability to diagnose and treat retinal diseases. Allogeneic sources of retinal tissue and 
cells can be obtained from donor eyes or cell lines. However, these are not clinically useful for 
confirming genetic diagnosis of a patient or for autologous cellular therapy. Access to patient-specific 
retinal tissue requires an intraocular procedure, called a vitrectomy, followed by detachment of the 
retina, retinectomy, laser retinopexy and a vitreous substitute to provide a temporary tamponade. 
Although this type of procedure is rarely performed for obtaining retinal tissue for the diagnosis of 
vitreoretinal lymphoma, there are significant blinding complications, such as retinal detachment, and 
the harvested retinal tissue will not be of adequate quantity or quality for disease modelling, retinal 
regenerative therapy or screening new therapeutics. Therefore, there is a clinical need for obtaining 
patient-specific retinal cells without the need to perform retinal biopsy. 
2.1. Creating iPSC from Patients 
2.1.1. Using Pluripotent Stem Cells 
An alternative method to obtain patient-specific retinal cells is to use patient-derived adult stem 
cells for differentiation into retinal lineages. Retinal neural and pigment epithelial progenitor  
cells [23,24] have been found in the adult retina, but access to these cells is also limited, as they will 
require vitrectomy surgery, making them equally unsuitable for clinical use in testing therapeutics and 
administering personalised cell therapy. Multipotent neural stem cells capable of generating retinal 
lineages have also been found in the ciliary margin zone and corneoscleral limbus [25–28]. The former 
source is located adjacent to the lens within the eye, and it is even more difficult to access than the 
retina. In contrast, limbal tissue is routinely harvested by corneal surgeons for autologous limbal 
transplantation. Despite the ease of limbal cell harvesting and the long-term safety of the limbal graft 
donor site [29,30], its use for retinal regeneration and disease modelling has not yet been explored due 
to limited data on the ability for in vitro expansion and the potential for differentiation into all retinal 
cell types. 
Unlike adult stem cells that are multipotent or unipotent, i.e., committed to specific cell  
types, pluripotent stem cells (PSCs) have a capacity for unlimited self-renewal (hence, large quantities 
of cells) and differentiation into any somatic cell type, including all classes of retinal cells. One source 
of PSC is the embryonic stem cells (ESCs), harvested from the inner cell mass of the blastocyst, from 
which each of the three germ layers—the endoderm, ectoderm and mesoderm—can be derived. 
However, ESCs are derived from discarded surplus embryos, and this is not patient-specific. Human 
ESC-derived RPE is currently being used in several clinical trials, but recipients are being 
immunosuppressed, because of the potential risk of graft rejection [12]. 
More recently, PSCs can also be generated by dedifferentiating a terminally differentiated  
patient-specific adult somatic cell, such as a fibroblast, into a pluripotent state by nuclear 
reprogramming. There are three established methods to induce pluripotency: (1) transfer of the nucleus 
of a differentiated cell into an enucleated oocyte (nucleus removed), so that pluripotency genes within 
the somatic cell genome are activated by the regulators within the oocyte cytoplasm (nuclear  
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transfer) [31]; (2) fusion of a somatic cell with an ESC to create a hybrid or heterokaryon in which 
pluripotency regulators override cell differentiation regulators (cell fusion) [32]; and (3) induced 
overexpression of specific pluripotency transcriptional factors through transfection of an adult somatic 
cell with integrating virus, non-integrating virus, plasmids, mRNA or even exposure to protein or 
small molecules (induced pluripotent stem cell (iPSC) reprogramming) [33]. 
2.1.2. Induced Pluripotent Stem Cells 
Since the original description of the iPSC protocol by Yamanaka [34], there has been significant 
development in the reprogramming approach, and many types of somatic cells have been successfully 
induced into a pluripotent state. Conceptually, this is a two-step process of (1) nuclear reprogramming 
of a chosen somatic cell into several clones of iPSC and (2) validation of the pluripotency of the 
various clones of iPSC to select the most suitable clone for the specific purpose that iPSCs will be 
used, for diagnostics or therapeutics. The time lag from biopsy to obtain patient’s somatic cells to full 
validation of the best iPSC clone may take 2–3 months. Several factors will influence the choice of 
somatic cell for deriving iPSC. 
For therapeutic purposes, such as autologous cell replacement therapy, the ideal iPSC clone should 
be derived from an easily accessible somatic cell type in facilities that comply with good 
manufacturing practice guidelines related to cell therapy. Both adult stem cells and differentiated cells 
have been used to derive good quality iPSC lines. Although adult stem cells may already express some 
of the pluripotency-related genes, their expression is significantly lower than that seen in ESC or iPSC. 
Therefore, the same protocol for deriving iPSC is generally required for adult stem cells as for 
differentiated cells. Cells that proliferate well also reprogram well. However, there is significant 
variability in genetic and epigenetic patterns and the degree of reprogramming, even between iPSC 
clones from the same cell source. Hu et al. showed that iPSCs derived from RPE retain a “memory” of 
cellular origin with respect to the propensity for differentiation back to RPE [35]. However, it will not 
be feasible to use patients’ RPE as a source for deriving iPSC, due to surgical complications associated 
with tissue harvest. Furthermore, even without “memory” in source cells, RPE and neuroretinal cells 
have been generated readily from iPSC derived from cells of diverse background, such as cord blood 
cell, lymphocyte, keratinocyte, adipocyte and fibroblast [2,4,36–38]. Another easily accessible source 
of somatic cells is the ocular surface. The potential to generate iPSC from cells on the ocular surface 
(corneal epithelium and limbal niche) warrants further investigation, as they can potentially be 
reprogrammed to pluripotency without the introduction of transcriptional factors, as shown in rodent 
limbal-derived neurospheres [39,40]. In contrast to autologous transplantation of iPSC-derived retinal 
cells, special consideration needs to be given to the ease of transport and storage of somatic cells for 
deriving iPSC for the purpose of genetic diagnosis, disease modelling and high throughput drug 
screening. In this situation, blood-derived cells (activated T lymphocytes and endothelial progenitor 
cells) may be preferable, as they are easily collected, transported, isolated and stored [41–43]. 
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The reprogramming protocol should preferably avoid the use of viruses, such as retroviruses, that 
were used to create the first human iPSC [34,44]. Non-integrating viral vectors, DNA plasmids, 
modified RNA, protein and small molecules have all been reported to induce a pluripotent state in a 
somatic cell [45–50]. There is no one perfect methodology for creating iPSC for all types of clinical 
use. The main trade-off for the potential mutagenesis by integrating virus is the lower efficiency and 
higher cost associated with non-integrating methods. There have also been variations on the 
transcriptional factors used for reprogramming since the original description by Yamanaka (OCT4, SOX2, 
KLF4 and c-MYC) and Thomson (OCT4, SOX2, NANOG and LIN28) (Figure 3) [34,44]. Some protocols 
also use additional small molecules, such as 5-aza-deoxycytidine, valproic acid or ascorbic acid, to modify 
the epigenetic environment and enhance the efficiency and accuracy of nuclear reprogramming. 
Ultimately, these protocol modifications will also have an impact on the cost and quality of the human 
iPSC line and the suitability for clinical application, such as autologous transplantation. Regardless of the 
cell source and reprogramming protocol, successful generation of retinal tissue from iPSCs will depend on 
the skills of the operator in identifying the “right” iPSC clones for retinal differentiation. 
Figure 3. Retrovirus vector for induced pluripotent stem cell (iPSC) reprogramming.  
(A) Map of polycistronic retroviral vector. Human fibroblasts two days after infection with 
polycistronic GFP Oct4/Sox2/Klf4/cMyc; (B) iPSC after four weeks post infection 
negative for GFP indicating that the transgene is silenced in iPSC clone. 
(A) 
(B) 
2.1.3. Validation of Human iPSC Lines 
The key defining features of iPSC are the self-renewal capacity and the ability to produce all three 
germ layers. Not all iPSC clones generated from the same somatic cell line from the same patient will 
J. Clin. Med. 2014, 3 1518 
 
 
be fully reprogrammed or truly pluripotent, and the efficiency of various protocols in generating iPSC 
clones can vary from 1:100 to 1:10,000. Screening to distinguish partially and fully reprogrammed colonies 
may add further delay and cost to the generation of patient-specific iPSC lines, and the thoroughness of this 
process depends on the clinical reasons for deriving the iPSC. It has been suggested that between five and 
10 clones may need to be isolated for characterisation and future differentiation, because not all clones will 
have the same propensity for retinal lineage derivation, despite their potential [6,7,51,52]. 
Four techniques are used for characterising and subsequently selecting iPSC clones: cellular, 
molecular, functional and genetic (Table 1). The extent of characterisation required will again depend 
on the purpose of generating iPSC. Less rigorous criteria may be sufficient for genetic diagnosis and 
disease modelling compared to drug screening and cellular therapy. However, a minimum set  
of criteria for establishing putative iPSC has been recommended by the European Consortium of stem 
cell research (the ESTOOLS project). 
The unpredictable variability between clones may be related to the somatic origin of iPSC, the 
reprogramming technique or the intrinsic clonal variability within the individual. Furthermore, equal 
performance of iPSC clones against the same “pluripotency” tests does not translate to equal 
propensity for retinal lineage derivation. Further investigation is required to establish a selection screen 
and criteria for reducing clonal variation and identifying iPSC clones that have optimal retinal 
differentiation propensity. It can be envisaged that different criteria for establishing pluripotency may 
emerge for diagnostic and therapeutic use of iPSC. 
2.2. Creating Retinal Tissue from iPSC 
2.2.1. Derivation of Retina Lineages 
The fundamental principles for differentiating iPSC into retinal progeny have been laid down by 
previous work on mouse and human ESCs. However, the different propensity between iPSC and ESC 
for retinal differentiation brings into question the validity of the various protocols proposed. Most of 
these protocols rely on the initial spontaneous induction of retinal differentiation, but there is variability 
between cell lines. The lack of reproducibility by other laboratories also raises concern regarding their 
utility in the clinical setting. Nevertheless, there are two broad approaches: one by default differentiation of 
iPSC into neuroectodermal lineages (upon withdrawal of FGF2) and the other through directed 
differentiation by the addition of extrinsic molecules, such as growth and transcription factors. 
A common approach in deriving retinal cells is to allow human iPSCs to overgrow as adherent 
layers. With the use of specific extracellular matrix in addition to certain inducing factors and proteins, 
iPSCs may be preferentially differentiated into RPE or photoreceptor phenotypes. For example,  
Tucker et al. described the formation of two-dimensional eyecup-like structures in a synthetic  
xeno-free culture substrate when skin keratinocyte-derived iPSCs were used [2]. After formation of 
small pigmented foci at around 45 days, these clumps expanded over 150 days. In some of these 
clumps, neural cells fill the centre, whilst in other colonies, pigmented cells wraps around in a C-shape 
around neural rosettes resembling a cross-section of an optic cup [2]. Similar two-dimensional eye-cup 
structures have also been reported by Jin et al. [53] and Reichman et al. [54]. 
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Table 1. Characterisation of induced pluripotent stem cells, photoreceptor cells and retinal pigment epithelium. 
Techniques of 
Characterisation 
Induced Pluripotent Stem Cells Photoreceptor Cells Retinal Pigment Epithelium 
Morphology  
(light microscopy) 
Flat colonies; small and round 
cells; high nuclear to  
cytoplasmic ratio 
Located in outer nuclear layer; cell bodies with 
processes; inner and outer segments 
Monolayer; pigmentation; hexagonal 
Morphology  
(electron microscopy) 
N/A 
Outer segment discs, myoid and ellipsoid 
segments, connecting cilia, basal body 
Apical microvilli, basal infoldings, tight-junctional  
complexes, pigment granules 
Cellular markers  
(pluripotency) 
Surface: SSEA-3, TRA-1-60, 
TRA-1-81; Others: NANOG, 
SOX2, OCT4 
Loss of OCT3/4, SOX2, NANOG Loss of OCT3/4, SOX2, NANOG 
Cellular markers 
(progenitors/precursors)
N/A PAX6, CHX10, CRX, OTX2, NRL PAX6, MITF 
Cellular markers 
(differentiated/mature) 
N/A 
Phototransduction: recoverin, transducing, cGMP 
phosphodiesterase, retinal guanylate cyclase, 
cyclic-nucleotide gated channel, rhodopsin, cone 
opsins (S or L/M), arrestin; visual cycle 
Visual cycle: RPE65, RLBP1, CRALBP; phagocytosis: FAK, 
MERTK; pigmentation: tyrosinase; growth factor: VEGF, 
PEDF, PDGF; membrane: Na/K ATPase, ZO-1, BEST1 
Molecular 
RT-PCR, bisulphite  
sequence analysis 
RT-PCR RT-PCR 
Functional (in vitro) Embryoid body formation Patch recordings; response to white flash 
Phagocytosis assay/rhodopsin clearance;  
fluid transport, polarised secretion of growth factors 
(PEGF/VEGF); transepithelial resistance 
Functional (in vivo) 
Teratoma assay in animal to 
identify all three germ layers 
Cell transplantation to demonstrate  
rescue of visual function 
Cell transplantation (RCS rat) to demonstrate  
rescue of visual function 
Genetic 
Karyotyping sequencing to  
look for new mutations 
Sequencing to check no new mutations Sequencing to check no new mutations 
RT-PCR, Reverse transcription polymerase chain reaction; RCS, Royal College of Surgeons. 
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An alternative approach is to culture iPSCs as suspended aggregates to enable the formation of  
three-dimensional cellular structures. Recapitulation of ocular organogenesis through the formation of 
an optic cup structure using a serum-free suspension culture system was first demonstrated using 
murine ESC by Eiraku et al. and then human ESC by Nakano et al. [55,56]. More recently,  
Meyer et al. described human iPSC-derived cell aggregates with vesicle-like and non-vesicular 
configurations after 20 days of culture using successive media changes from embryoid body medium 
(four days) to neural induction medium (seven days) and, finally, to retinal differentiation  
medium [6,51]. The vesicle-like structures expressed CHX10, a marker of retinal progenitor cells, 
whereas the non-vesicular spheres expressed ISLET-1, a homeodomain protein involved in early 
forebrain development. Upon further differentiation, photoreceptor-like cells and RPE were derived 
from the vesicle-like structures. Similar optic vesicle-like structures have also been generated from 
lymphocyte-iPSC [4,36]. Zhong et al. recently reported three-dimensional laminated retinal cups 
generated from human iPSC with distinct populations of neural retinal cells interacting through 
synaptic junctions and photoreceptor cells capable of forming outer segment discs and responding to 
light [57]. However, it is important to note that efficiency in generating PAX6+ neuroectodermal cells 
amongst different iPSC clones can vary from 5% to 56% of the total cell population using the same 
protocol, highlighting the need for further investigation into the methods and screening criteria to 
identify the most suitable iPSC clone for retinal differentiation [51]. 
Irrespective of the protocol used for inducing retinal differentiation, the timing of the derivation of 
specific retinal cell types generally reflects the timeline of embryological development. This temporal 
recapitulation of embryogenesis by iPSC differentiation supports the notion that derivation of retinal 
cells is not directed, but rather the outcome of subcloning and culture in a permissive 
microenvironment. During the first month of embryonic development, the forebrain portion of the 
primitive anterior neuroepithelium gives rise to cells expressing markers specific for the eye field. 
Optic vesicles then develop from the eye fields at the end of the first month with cells expressing 
PAX6 and MITF. Retinal progenitors destined to become RPE preferentially express MITF, whereas 
those becoming neuronal cells downregulate MITF in response to increased CHX10 expression. Then, 
there is a 1–2 month(s) lag in the expression of CRX and opsin genes in neural retinal cells after the 
formation of RPE. Hence, the time to generate RPE from iPSC is typically around 4–6 weeks, whereas 
differentiation of photoreceptor precursors occurs at 2–3 months after retinal induction. Formation of 
outer segments and the development of light response was reported by Zhong et al. at six months after 
retinal induction [57]. Recently, Reichman et al. described a floating culture system for generating  
neuroretinal-RPE containing retinal progenitor cells within two weeks, which bypassed embryoid body 
formation and obviated the need for exogenous molecules, coating or Matrigel [54]. 
The ability to recapitulate retinogenesis using iPSC has tremendous potential for studying diseases 
that interfere with retinal development and non-cell autonomous mechanisms, in addition to those that 
cause post-natal cell autonomous retinal degeneration. On a practical level, there are still significant 
barriers to routine clinical use of this technology, since the generation of patient-specific retinal cells may 
take 4–6 months from the time of biopsy, and there is significant overhead infrastructure cost to maintain 
an iPSC laboratory. Future advancement in three-dimensional culture and differentiation techniques may 
one day enable iPSCs to differentiate into other structures of the eye, such as the choroid and sclera, thus 
expanding the use of iPSC in understanding complex retinal diseases, such as AMD and myopia. 
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2.2.2. iPSC to Photoreceptor Cells 
Hirami et al. described deriving photoreceptor cells using human iPSC from dermal fibroblast,  
serum-free embryoid body culture system, defined factors (Wnt and Nodal inhibitors) and subsequent 
plating of aggregates onto poly-D-lysine, laminin and fibronectin to generate retinal progenitors 
expressing RX, PAX6 and MITF [58]. From Day 90, the application of retinoic acid and taurine to the 
culture system induced the expression of the photoreceptor marker, recoverin, in a quarter of the 
colonies by Day 120 (four months). Half of these recoverin-positive cells were also immune-positive 
for rhodopsin. Notably, only two of three iPSC lines could be differentiated into the retinal lineage, 
and functional assays of putative photoreceptor cells were not performed. Osakada et al. from the same 
group, at the RikenCenter for Developmental Biology, also reported a modified protocol using small 
molecules (casein kinase I inhibitor CKI-7, Rho-associated kinase inhibitor Y-27632 and ALK4 inhibitor 
SB-431542) to block Wnt and Nodal pathways to induce retinal progenitors [59]. This method has been 
used in generating photoreceptor cells from patients with RP1, RP9, PRPH-2 and RHO mutations [7,53]. 
Meyer et al. [51] described a different culture system using embryonic stem cell medium without 
FGF2, then chemically-defined neural induction medium with N2 supplement followed by another 
chemically-defined retinal differentiation medium supplemented with B27. Rosettes were picked and 
selected for neurosphere culture and generation of optic vesicle-like structures. By Day 80, 14% of the 
neurospheres expressed rod- and cone-specific transcription factor Crx, within which 65% of the cells 
were expressing Crx. However, only 8% of the cells within Crx+ spheres expressed recoverin and/or 
opsin. This protocol was modified by Zhong et al. to generate photoreceptor cells (within laminated 
retinal cup structure) that express synaptic junction proteins, phototransduction molecules, to form 
outer segments and to respond to light stimulus [57]. The optic vesicle-like system was used to study 
the effect of CHX10 mutation [4]. 
Several other groups have also described the derivation of photoreceptor cells from human iPSC  
(Table 2). There are many morphological, cellular, molecular, functional and genetic assays for the 
characterisation of iPSC-derived photoreceptors and their precursors, but there is no consensus on the 
minimum criteria (Table 1). Lamba et al. used their protocol for ESC [60] to derive photoreceptor cells 
from human iPSCs [52]. Although, they did not test the function of these cells, they demonstrated 
integration into mouse retina following sub-retinal transplantation. Mellough et al. combined the 
techniques described by Lamba et al. and Osakada et al. for deriving retinal cells from ESC and added 
activin A, Shh and T3 to enhance photoreceptor differentiation from human iPSCs [60–62].  
Their three-step differentiation protocol involved inducing a neural lineage, then retinal progenitors 
and, finally, photoreceptor cells expressing blue, red and green opsin. For iPSC-derived photoreceptor 
cells to be used in human transplantation, animal-derived products should be avoided where possible.  
Tucker et al. and Sridhar et al. recently reported the generation of photoreceptor cells from iPSCs 
using a xeno-free system, where a synthetic culture surface (Synthemax cell culture surface) is used for 
iPSC derivation and retinal differentiation [37,63]. 
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Table 2. Derivation of retinal photoreceptor (precursor) cells from human induced pluripotent stem cells. 
Reference Source of iPSC Duration 
Markers to Confirm 
Photoreceptor Lineage 
Tests to Suggest Photoreceptor 
Cell Function 
Transplant
Disease 
Modelling
Therapeutics 
Screening 
Hirami et al. [58] Human fibroblast 120 days CRX, RCVRN, RHO No No No No 
Osakada et al. [59] Human fibroblast 120–140 days
CRX, PDC, PDE6b, PDE6c, 
RHO, GRK1, SAG, RCVRN 
Molecules required for  
photo-transduction 
No No No 
Jin et al. [7] Patient fibroblast 120 days 
CRX, RCVRN, RHO,  
OPN1SW, OPN1LW 
Patch clamp to detect voltage 
dependent channels 8-OHdG, 
caspase-3, acrolein, BiP, CHOP 
No Yes Yes 
Jin et al. [53] Patient fibroblast * 120–150 days CRX, RCVRN BiP, CHOP No Yes No 
Meyer et al. [51] Human fibroblast 80 days CRX, RCVRN, Opsin No No No No 
Meyer et al. [6] Patient fibroblast 80 days CRX, RCVRN No No No No 
Phillips et al. [36] Patient T-cells 108 days 
CRX, RCVRN, S-OPSIN, RHO, 
CX36, SNAP-25, VGLUT1 
Molecules required for  
synaptic function 
No No No 
Phillips et al. [4] Patient T-cells 80 days 
CRX, RCVRN, NRL,  
OPN1SW, PED6B 
Molecules required for  
photo-transduction 
No Yes No 
Tucker et al. [3] Patient fibroblast 33 days RCVRN No No Yes No 
Tucker et al. [2] Patient keratinocyte 60 days 
CRX, NRL, RCVRN, RHO, Acy 
Tubulin, OPN1SW, OPN1LW 
GRP78, GRP94 Yes Yes No 
Burnight et al. [64] Patient fibroblast 90 days 
CRX, RHO, OPN1SW,  
RCVRN, ROM1 
No No No Yes 
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Table 2. Cont. 
Reference Source of iPSC Duration 
Markers to Confirm 
Photoreceptor Lineage 
Tests to Suggest Photoreceptor 
Cell Function 
Transplant
Disease 
Modelling
Therapeutics 
Screening 
Tucker et al. [37] 
Patient fibroblast, 
Human keratinocyte 
and IPE *,† 
90 days CRX, NRL, RCVRN, RHO No No No No 
Sridhar et al. [63] Human fibroblast 60 days CRX, RCVRN No No No No 
Mellough et al. [62] Human fibroblast 60 days 
CRX, OPN1SW, OPN1LW, 
RHO, RCVRN, ARRESTIN 3 
No No No No 
Reichman et al. [54] Human fibroblast 49–112 days
CRX, NRL, RHO, R/G/B OPSIN, 
ARRESTIN 3, RECVRN 
No No No No 
Zhong et al. [57] Human fibroblast 175 days 
CRX, OPN1SW, OPN1LW, 
RHO, PDE6α/β, Gtα, 
CNGA1/B1, RetGC1 
Patch clamp-light induced 
response; outer segment disc 
formation on EM; molecules 
required for photo-transduction 
No No No 
Lambda et al. [52] Human fibroblast 28 days 
CRX, OTX2, NRL, RECVRN, 
AIPL-1, RHO, S-Opsin, Arrestin, 
PAX6, Blimp1 
Molecules required for  
photo-transduction 
No No No 
Yoshida et al. [8] Patient fibroblast 35 days NRL promoter, recoverin 
BiP, CHOP, BID, NOXA LC3, 
ATG5, ATG7 
No Yes No 
8-OHdG, 8-Hydroxy-2′-deoxygunosine (oxidative stress marker); BiP, Binding immunoglobulin protein; CHOP, C/BEP-homologous protein/DNA-damage-inducible 
transcript 3; RCVRN, Recoverin; * iPSC derived from integration-free iPSC; † iPSC derived from xeno-free culture. 
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2.2.3. iPSC to Retinal Pigmented Epithelial Cells 
Although the embryoid body culture system can generate RPE from iPSC, adherent culture has 
been favoured if RPE is the only cell that is required. Hirami et al. and Meyer et al. showed RPE 
differentiation occurs earlier than neural retinal progeny derivation [51,58]. Carr et al. and  
Buchholz et al. demonstrated that RPE differentiation from human iPSC can be achieved within four 
weeks, and these cells demonstrated morphological and molecular signatures of RPE, as well as  
in vitro and in vivo functional characteristics [65,66]. Morphologically, RPE derived from iPSCs is 
indistinguishable from RPE in post-mortem eye or human ESC-derived RPE (Figure 4). 
Figure 4. Morphology of the retinal pigment epithelium monolayer. (A) Hexagonal 
pigmented monolayer of retinal pigment epithelium derived from induced pluripotent stem 
cells; (B) Comparison of the morphology of retinal pigment epithelial stem cells derived 
from human embryonic stem cells (HESC), post-mortem (PM) eyes and induced 
pluripotent stem (iPS) cells. 
 
(A) 
 
(B) 
Characterisation of iPSC-RPE involves morphological, cellular, molecular, functional and genetic 
assays (Table 1). Key morphological features include pigmentation, monolayer of hexagonal cells and 
electron microscopic features of apical microvilli, tight junctions, basal infoldings and cytoplasmic 
melanosomes. The molecular signature of RPE cells reflects their eye field origin (PAX6 and MITF) 
and function: RPE65 and CRALBP (retinoid cycle), MERTK (phagocytosis), bestrophin (modulating 
calcium flux in endoplasmic reticulum) and ZO-1 (tight junctions). In vitro functional assessment 
includes transepithelial resistance measurement, vascular endothelial growth factor (VEGF),  
platelet-derived growth factor (PDGF) and pigment epithelium-derived factor (PEDF) secretion, 
extracellular matrix production (laminin and type IV collagen) and phagocytosis assay using 
J. Clin. Med. 2014, 3 1525 
 
 
photoreceptor outer segments. In vivo functional assessment requires subretinal transplantation in an 
animal model of RPE or retinal dystrophy, such as the Royal College of Surgeons (RCS) rat, to assess 
the rescue of visual function [65,67–69]. Gene expression comparing human iPSC-RPE to adult and 
foetal RPE and other controls through microarray and hierarchical clustering analysis needs to be 
performed to verify similarity to target tissue [70]. 
For autologous transplantation of iPSC-RPE, immunogenicity, cell survival and tumourigenicity 
studies are also required. These have been addressed for iPSC-RPE specifically by Kamao et al. and  
Kanemura et al. [70,71] as part of a pre-clinical study in preparation for human iPSC-RPE autologous 
transplantation. The generation of patient-specific iPSC-RPE has also been performed in gyrate 
atrophy and Best disease (BD) [5,6]. The following section will illustrate clinical examples of the use 
of iPSC-derived retinal cells in genetic diagnosis, discovery of genotype/phenotype relationship, 
screening of pharmaco- and gene therapies and as a source of autologous cell therapy. 
3. Clinical Use of Patient-Specific iPSC-Derived Retinal Cells 
The ability to generate patient-specific retinal tissue and cells offers the opportunity to study the 
relationship between genetic variants and disease phenotypes. This technology is particularly useful in 
modelling IRDs, as there are around 200 genes with over 4200 known and many other unknown 
mutations causing disease phenotype in IRDs [72]. One in 2000–3000 individual are affected by IRDs, 
and these, collectively, are the most common cause of blindness in children and young adults.  
Given that emerging therapies for IRDs are likely to be mutation specific, it is important to identify 
pathogenic mutation(s) in every affected individual [73–75]. 
Many IRDs have a poor genotype-phenotype correlation; defects in a single gene may lead to a 
variety of disease phenotypes, while, on the other hand, a particular disease phenotype may be caused 
by mutations in a large number of different genes. Adding to the challenge of identifying causative 
mutations is the relatively common occurrence of X-linked and de novo autosomal dominant variants. 
Although Sanger sequencing of selected genes followed by targeted next-generation sequencing 
(NGS) can identify known pathogenic mutation in many individuals, exome or whole genome NGS 
combined with genetic linkage studies are required for the identification of novel mutations. 
Traditionally, these rare mutations (<1%) have been validated through functional modelling, mouse 
and zebrafish studies and replication of genotyping in large patient and relevant control cohorts. More 
recently, iPSC technology has also been used to confirm the pathogenicity of genetic variants and to 
unravel the molecular mechanism of disease phenotype through the in vitro study of cellular function 
and the histogenesis of iPSC-derived retinal tissue. 
3.1. IPSC for Genetic Diagnosis and Modelling 
3.1.1. Confirming Pathogenicity of Mutation 
Patient-specific iPSC has been used to confirm the pathogenicity of new rare genetic variants.  
For example, using NGS, single-strand conformation polymorphism screening and Sanger sequencing 
of a large validation cohort, Tucker et al. [3] identified a new mutation (Alu element insertion) in the 
male germ cell-associated kinase (MAK) gene causing rod-cone dystrophy. This was confirmed by 
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examining and comparing the transcripts of MAK between iPSC and iPSC-derived photoreceptors 
from the patient and his unaffected sibling. The proband had no family history of retinal dystrophy, 
and the affected individual was heterozygous for pathogenic variants in ABCA4 and USH2A. Using 
iPSC, they discovered a previously unrecognized exon 12 of the MAK gene that is expressed in cells 
differentiated into retinal precursors, but not in undifferentiated cells. This observation confirmed that 
the homozygous Alu element insertion in exon 9 is pathogenic by affecting the developmental switch 
from MAK bearing only exon 9 to a retina-specific transcript bearing both exons 9 and 12. The 
insertion of a 353-bp Alu repeat between codons 428 and 429 in exon 9 results in the insertion of 31 
incorrect amino acids followed by a premature termination. In another study, Tucker et al. [2] reported 
the discovery of a new pathogenic variant of USH2A in another patient with rod-cone dystrophy who 
was presumed heterozygous for a pathogenic variant in ABCA4 and USH2A. The second possibly 
disease-causing variant was found in intron 40 of USH2A, and this was confirmed by real-time PCR of 
patient-specific iPSC-derived photoreceptor precursor cells. A pseudoexon (IVS40) was formed by the 
intronic splice site mutation in the intervening sequence 40 of USH2A, and this caused a translation 
frameshift and a premature stop codon. 
Lustremant et al. [76] examined the transcriptomics of human iPSC-derived neural stem cells and 
RPE from two patients with Leber congenital amaurosis (LCA). Although the pathogenic mutation 
was not known, they showed changes in the expression of 21 genes when compared to wild-type 
controls. Amongst these, three downregulated genes—TRIM61, ZNF558 and GSSTT1—were related to 
the LCA disease process through protein degradation, altered transcription regulation and oxidation. 
With better understanding of the interactions between molecular pathways, detection of altered 
transcriptomics may help to narrow down candidate genes in this patient with LCA. 
3.1.2. Modelling Developmental Diseases of the Retina 
The impact of known mutations on retinogenesis and cellular function has also been explored.  
The transcription factor CHX10 (Caenorhabditis elegans Ceh-10 homeo-domain-containing  
homolog 10), also known as VSX2 (visual system homeobox 2), has a critical role in the development 
of the retina. The very rare mutation in VSX2 leads to severe malformation of the eye. Although animal 
models of this disease (the VSX2−/− and (R200Q) VSX2 mice) have contributed greatly to our 
understanding of the importance of VSX2 in repressing MITF, production of the bipolar cell and 
maturation of the photoreceptors, it was not possible to confirm that the same mechanism occurs in 
humans. Phillips et al. [4] used iPSCs from a patient with a (R200Q) VSX2 mutation to generate an 
embryoid body and then vesicles that recapitulated retinogenesis [6,36]. They confirmed previous 
observations in animal models and went a step further, using lentiviral VSX2 overexpression to 
examine the reversibility of the developmental defect in vitro. Although suppression of MITF and 
enhanced photoreceptor maturation was achieved, bipolar cell markers were not restored by wild-type 
lenti-VSX2. Transcriptome analysis at Day 20 and 30 cells demonstrated overall upregulation of genes. 
Most of these were related to the WNT and TGFb signalling pathways that promote  
RPE differentiation. In contrast, the FGF pathway, which promotes neuroretinal differentiation,  
was downregulated. 
J. Clin. Med. 2014, 3 1527 
 
 
The process of deriving retinal cells from iPSCs provides an opportunity for studying retinal 
development and developmental anomalies due to specific mutations that cause ocular and retinal 
dysgenesis (e.g., MITF, PAX6, VSX2, CRB1, etc.). However, terminally differentiated retinal cells 
from iPSCs can also be tested for altered cell function to understand degenerative diseases of the retina  
(see below). IRDs that have an earlier onset may be expected to demonstrate abnormality earlier in the 
differentiation protocol, whilst late onset IRDs (e.g., BD, pattern dystrophy, Sorsby fundus dystrophy 
and Doyne honeycomb retinal dystrophy) may not manifest altered cellular physiology unless the cells 
are aged and stressed in vitro to recapitulate senescence. 
3.1.3. Modelling Degenerative Diseases of the Retina 
Both RPE and photoreceptor disease models have been created using patient-specific iPSCs.  
AMD (Figure 5) and two types of RPE dystrophies have been modelled: Best disease and  
gyrate atrophy. 
Figure 5. Clinical images of early age-related macular degeneration and its variants.  
(A) Colour photograph of the macula of a 72-year-old male showing soft drusen; (B) 
Optical coherence tomography (OCT) shows a sub-retinal pigment epithelial (RPE) 
deposit, which did not significantly alter fundus autofluorescence (C); (D) Colour 
photograph of the macula of a 78-year-old female showing reticular pseudo-drusen; (E) 
OCT shows deposits above the RPE, resulting in subtle hypo autofluorescent lesions (F); 
(G) Colour photograph of the macula of a 57-year-old female showing basal laminar 
drusen; (H) OCT shows a compact sub-RPE deposit forming a saw-tooth pattern, and these 
lesions were mildly hyper autofluorescent (I); (J) Colour photograph of the macula of an 
83-year-old female showing dominant drusen or Doyne honeycomb retinal dystrophy; (K) 
OCT shows outer retinal layer loss; (L) The fovea was hypo autofluorescent due to RPE 
loss, and the linear radial drusen are seen as hyper autofluorescent streaks. 
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Chang et al. reported reduced ZO-1 and RPE65 staining in iPSC-RPE generated from five atrophic 
AMD patients compared to two controls [38]. There was also increased accumulation of reactive 
oxygen species following exposure to H2O2 compared to controls. Furthermore, expressions of 
antioxidant genes (HO-1, SOD2 and GPX1) were lower, whilst PDGF, VEGF and IGFBP-2 
expressions were higher compared to controls. There were no details regarding the age of the two 
control subjects, and the AMD risk allele profiles for all seven subjects were not reported. Further 
studies are needed to replicate these findings by controlling other potential confounders. It is particular 
important that control subjects are age matched when iPSC is used to model late-onset degeneration as 
AMD. This is because AMD cannot be diagnosed until drusen is visualised, usually after the age of  
50 years. Although the presence of risk alleles and family history increases the risk of developing 
AMD, these biomarkers are not 100% predictive. Therefore, somatic cells from young healthy 
individual cannot be used as controls, because it is not possible at this stage to predict if this subject 
will or will not develop AMD later in life. 
Heterozygous, compound heterozygous and homozygous mutation of the BEST1 gene (bestrophin 
protein) can cause ocular disease characterised by abnormal RPE function, accumulation of debris 
between RPE and photoreceptors and a variable amount of retinal degeneration and ocular dysgenesis 
(Figure 6). There are over 100 mutations in BEST1, and the pathogenicity and molecular mechanism of 
RPE dysfunction arising from these mutations is not well understood. The traditional approach to 
study the effects of BEST1 mutation is based on transfection of mutant BEST1 gene into the human 
foetal RPE or Madin Darby canine kidney (MDCK II) epithelium cell lines. Sing et al. described the 
use of RPE derived from patient-specific iPSCs to study the impact of two mutations in the BEST1 
gene, (A146K and N296H) on RPE function. They demonstrated increased intracellular accumulation 
of autofluorescent materials compared to controls after long-term (3.5 months) feeding of the BD  
hiPSC-RPE with bovine photoreceptor outer segments (POS, 50/cell) and decreased net fluid transport. 
Conflicting data at 4 and 24 hours were shown regarding delayed degradation of POS when overfed 
with FITC-POS (50 vs. 20 POS per cell). As expected, there was no significant difference in the RPE 
differentiation potential of BD hiPSC compared to controls. BD hiPSC-RPE also had a similar 
transepithelial resistance, level of BEST1 mRNA and localisation pattern of the mutant bestrophin 
compared to controls. The dysfunction in mutant bestrophin was found to be associated with altered 
endoplasmic reticulum (ER)-mediated calcium homeostasis. Furthermore, there was increased 
expression of genes involved in regulating oxidative stress (GPX1, SOD2) and iron homeostasis  
(TRF, TRFR) after long-term (3.5 months) POS feeding [5]. In this study, the genetic background 
between the cell lines was not controlled by genomic editing of the BEST1 mutation into the control 
iPSC or out of the BD hiPSC (see below). Nevertheless, this is a good example where early onset 
disease with a well-characterised clinical disease phenotype can be recapitulated in vitro. It is not 
known if similar cellular abnormalities can also be detected in iPSC-RPE from patients with the much 
commoner late-onset vitelliform macular dystrophy due to other types of BEST1 mutations. 
Phagocytosis assay may be a better readout for iPSC-RPE generated from patients with a known 
genetic defect that impairs phagocytosis, such as MERTK or REP-1 mutation (choroideremia). 
In a very different RPE dystrophy, gyrate atrophy, homozygous mutation in the  
ornithine-δ-aminotransferase gene (OAT) leads to RPE damage and loss, leading to severe peripheral 
and central vision loss. RPE has been successfully generated from iPSCs derived from the fibroblasts 
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of a patient with OAT mutation (A226V). Enzyme activity of OAT within the iPSC-RPE can be  
measured [6]. Correction of the OAT mutation by bacterial artificial chromosome-mediated 
homologous recombination restored the enzymatic activity [77]. There are other RPE dystrophies 
resulting from mutations affecting visual cycle enzymes or regulators (e.g., the acyltransferase, LRAT, 
the isomerohydrolase, RPE65, the dehydrogenase, RDH12, and RPGR and RLBP1). Deriving  
iPSC-RPE from patients with various genetic mutations in these enzymes or regulators may also 
provide opportunities to understand genotype-phenotype molecular mechanisms and variability. 
Figure 6. Clinical images of various types of inherited retinal diseases. (A) Colour 
photograph of the macula of a 10-year-old boy showing multifocal vitelliform lesions 
resulting from homozygous deletion of exon 2–6 of the BEST1 gene; (B) Optical 
coherence tomography (OCT) shows intraretinal cystic change with sub-retinal fluid and 
vitelliform deposits; (C) Increased fundus autofluorescence was noted in the area of 
vitelliform deposits; (D) Colour photograph of the macula of a 57-year-old male showing 
yellow deposits due to pattern dystrophy of the retinal pigment epithelium (RPE); (E) OCT 
shows deposits above and below the RPE; (F) Multifocal hyper autofluorescent lesions are 
seen; (G) Colour photograph of the macula of a 56-year-old female showing extensive 
macular atrophy with cone-rod dystrophy due to two missense mutations in the ABCA4 
gene (c.2915 C > A and c.3041 T > G); (H) OCT shows severe retinal and choroidal 
atrophy with pigment migration into the fovea; (I) Extensive RPE loss resulting in  
wide-spread hypo autofluorescent lesions; (J) Colour photograph of the macula of a  
32-year-old male showing retinal flecks with mild cone dysfunction due to two pathogenic 
mutations in the ABCA4 gene (c.4139 C > T and c.6079 C > T); (K) OCT shows outer 
retinal layer loss to retinal atrophy; (L) Retinal flecks were hyper autofluorescent. 
 
Many genes are involved in photoreceptor cell degeneration. Clinically, there are two broad classes 
of disease phenotypes based on electrophysiology: macular dystrophy, which is limited to the macular 
region, and retinal dystrophy, where the entire population of photoreceptors (central and peripheral) is 
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affected. Generalised retinal dystrophy can affect cones or rods predominantly. Different mutations in 
one gene, such as ABCA4, can have varied disease phenotypes, including macular dystrophy, cone 
dystrophy, cone-rod dystrophy or rod-cone dystrophy (Figure 6). The overlap between various disease 
phenotypes and causative mutation reinforces the importance to understand the molecular mechanisms 
of genotype-phenotype relationships. 
Amongst the genes causing rod-cone dystrophy, the molecular effect of mutations in RHO, RP1, 
RP9, PRPH-2 and USH2A have been studied using iPSCs. Jin et al. [7] used iPSCs from patients with 
RHO, RP1, RP9 and PRPH-2 to generate rod photoreceptor precursors. They demonstrated reduced 
rod cell number at Day 120 in iPSC-rod precursors derived from patients with RP9 mutation  
(early-onset retinal degeneration). This effect was seen in RHO, RP1 and RHO mutation at Day 150, 
whereas no rods were detectable for the iPSC line carrying the RP9 mutation. They also showed that 
the RP9 mutant iPSC-rod precursors had increased oxidative stress. In contrast, the RHO mutant  
iPSC-rod precursors had mislocalisation of the rhodopsin protein and increased expression of ER 
stress markers, which might be explained by the accumulation of unfolded rhodopsin [7,53].  
Tucker et al. also examined the impact of USH2A mutation on photoreceptor precursor cells. They 
described increased expression of GRP78 and GRP94 in iPSC-derived photoreceptor precursor cells, 
indicative of ER stress related to protein misfolding. It is important to note that controls used in these 
reports were not genetically matched, i.e., the mutation was not removed by genomic editing. 
A major limitation of these genotype-phenotype studies is the choice of controls. For metabolic 
syndromes or disease with early manifestation (ocular dysgenesis or early degeneration), healthy 
related or unrelated controls will be adequate, because of the robust and rapid cellular manifestation of 
the phenotype. However, controls used for studying diseases with delayed onset will need to be 
genetically matched to avoid the cofounding effect of the (1) genetic background, (2) retinal cell 
differentiation process and (3) genetic alteration introduced during the process of iPSC reprograming. 
Yoshida et al. confirmed the effect of RHO mutation (E18K) on rod precursor cell ER stress responses, 
apoptosis markers and autophagy activation by repairing and introducing the mutation in the affected 
and control (provided by Yamanka laboratory) cell lines, respectively, using a helper-dependent 
adenoviral vector gene transfer [8]. Similar genetic control was also reported for gyrate  
atrophy-iPSC-RPE, where restoration of the OAT gene in the iPSC using bacterial artificial 
chromosome-mediated homologous recombination resulted in normalisation of OAT enzyme activity 
in iPSC-RPE [6,77]. 
Once the clinically-relevant cellular phenotype and readouts can be defined for the specific genetic 
variant and mutation, high throughput analysis will need to be developed to enable a large number of 
therapeutics to be screened across the potential thousands of genetic variant cell lines from patients 
with IRDs. Although this is not yet possible, there are several examples where this has been reported 
on a smaller scale (see below). Further investigations are needed to determine if late-onset retinal or 
macular degeneration, such as reticular pseudodrusen (Figure 5), basal laminar drusen (Figure 5), 
pattern dystrophy of the RPE, vitelliform macular dystrophy and mutations arising from EFEMP-1 
(Doyne honeycomb retinal dystrophy, Figure 5), TIMP-3 (Sorsby fundus dystrophy) or CTRP5  
(late-onset retinal degeneration), can also be modelled through derivation of retinal cells from iPSCs. 
The readout or functional assay for each of these diseases may differ significantly because of variable 
environmental contribution to the disease phenotype and diverse molecular pathogenic mechanisms. 
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For example: Sorsby fundus dystrophy may be caused by deposition of abnormal extracellular protein 
(TIMP-3); Doyne honeycomb retinal dystrophy may be related to activation of unfolded protein 
response due to misfolded fibulin-3 (EFEMP-1); and late-onset retina degeneration may be associated 
with abnormal intracellular protein aggregates, as well as extracellular deposition [78–81]. There are 
also many IRDs that affect retinal cells downstream from the photoreceptors, such as congenital 
stationery night blindness and X-linked retinoschisis [82]. Patient-specific iPSC-derived laminated 
retinal structures may be ideal for the study of pathophysiology of these inner retinal IRDs, since many 
of the genes involved in these diseases (e.g., NYX, CACNA1F, GRM6, TRPM1, CABP4, CACNA2D4 
and RS1) are involved in the extracellular matrix of neural retina and the synaptic interaction between 
photoreceptor and bipolar cells [83]. 
3.2. IPSC for Therapeutics Development and Treatment 
3.2.1. IPSC for Drug Screening 
Current therapeutic modalities in IRDs are aiming to preserve residual cells or replace missing cells. 
Because gene therapies and many pharmacotherapies will need to be tailored for individual genetic 
variants or mutations, iPSCs provide an ideal platform for pre-clinical therapeutic and toxicology 
testing. There are several examples in both AMD and IRDs, where pharmaco- and gene therapies are 
tested using iPSC. 
Chang et al. tested the protective effect of curcumin on iPSC-RPE derived from AMD patients [38].  
They showed that curcumin had a beneficial effect on H2O2-induced cell death and reactive oxygen 
specifies generation in both control and AMD iPSC-RPE. Exposure of curcumin also increased the 
expression of HO1, SOD2 and GPX1 and decreased the expression of PDGF, VEGF and IGFBP-2 in 
AMD iPSC-RPE. Whether this also occurred in control iPSC-RPE was not reported. 
OAT deficiency in the RPE leads to a buildup of ornithine and a reduction in high-energy creatine 
phosphate. In some patients, the OAT enzymatic activity can be reversed by a high dose pyridoxine 
(vitamin B6) supplement, because of the effect of OAT mutation on the binding affinity to pyridoxine. 
Clinically, vitamin B6 responsiveness is tested in patient fibroblasts. Although based on the fibroblast 
assay, A226V OAT mutation is not responsive to vitamin B6, Meyer et al. has demonstrated that  
iPSC-RPE from this patient is, in fact, responsive to vitamin B6 based on an in vitro dose titration 
experiment. Therefore, this patient has directly benefited from iPSC disease modelling and 
pharmacotherapy screening. 
Jin et al. [7] demonstrated the benefit of α-tocopherol (vitamin E) on improving the survival of  
iPSC-rod precursor cells in the RP9 mutation. They also confirmed no toxic effect from 1.6 μM of 
ascorbic acid (vitamin C) and β-carotene (vitamin A) on iPSC-rod precursors affected by RP1, RP9, 
PRPH-2 and RHO mutations. In addition to vitamins, modulators of signal pathways have also been 
screened using iPSC. Yoshida et al. showed that inhibition of mTOR (using rapamycin or PP242), 
activation of AMP kinase (using AICAR), inhibition of apoptosis signal-regulating kinase (using  
NQDI-1) and inhibition of protein synthesis (using salubrinal to inhibit eukaryotic translation initiation 
factor 2 subunit α phosphatase) can reverse the increased ER stress and apoptosis and autophagy 
marker expression seen in RHO mutant iPSC-rod precursor cells [8]. 
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3.2.2. IPSC for Testing Gene Therapy 
In addition to screening prospective pharmacological agents, iPSC has also been used to test the 
efficacy of gene therapy approaches in LCA and choroideremia, which aim to deliver the CEP290 and 
REP-1 genes, respectively, to retinal cells. CEP290 is a centrosomal protein involved in ciliogenesis 
and ciliary trafficking. Mutation in CEP290 leads to abnormality of the inner and outer segments of 
cone cells, resulting in early-onset severe visual loss. Previous ocular gene therapy used  
adeno-associated viral (AAV) vectors for delivery of the RPE65 gene. However, the large size of 
CEP290 precludes the use of AAV, and therefore, lentivirus is necessary for gene delivery.  
Burnight et al. [64] described the method to package full-length human CEP290 into a lentiviral vector 
and demonstrated restoration of a ciliogenesis defect in LCA patient-derived fibroblasts. Although 
they also demonstrated expression of wild-type CEP290 after lentiviral transduction of the  
iPSC-photoreceptor precursor cells, they did not examine the impact of this on cone development and 
the formation of inner or outer segments. In contrast, Vasireddy et al. [84] showed successful 
transfection of AAV2 carrying full-length human REP-1 cDNA into iPSCs rather than transfection 
into differentiated retinal cells, the presumed target cell primarily affected in choroideremia. They used 
a prenylation assay to confirm restoration of REP-1 function following AAV2. REP-1 infection of the 
iPSC. There was also improved trafficking of RAB27 in iPSCs, because of prenylation by  
viral-derived REP-1. The efficiency and toxicity of iPSC transduction was compared to patients’ 
fibroblasts, but not patient-derived iPSC-RPE. These two examples demonstrate the potential of iPSC 
in pre-clinical studies of patient-specific gene therapy. 
3.2.3. iPSC for Cellular Therapy 
Cell therapy for retinal disease aims to replace (1) photoreceptors and/or (2) supporting cells that 
provide trophic and metabolic support to prevent further degeneration of remaining photoreceptors.  
The main challenges in establishing clinically acceptable cell therapy for retinal disease are: patient 
selection, surgical technique, carrier system and choice of cell source. Each of these questions has its 
complexity in several dimensions. However, the use of iPSCs as a source for retinal cell 
transplantation is one of the most exciting, but also complex and challenging, issues facing scientists, 
clinicians, pharmaceutical companies and regulatory authorities. 
In comparison to human ESC, the use of iPSC-derived cells for cell therapy has the additional 
requirement of quality control associated with the surgical procedure in harvesting patient somatic 
cells, isolation of a single cell type from the tissue biopsy, reprogramming vectors and techniques, 
methods of genomic editing in the case of IRDs and techniques of hiPSC clone selection and storage. 
Some of these steps have been defined in standard operating procedures for the production of  
clinical-grade iPSCs from retrovirus reprogramming. However, this is yet to be established for the 
numerous published non-integrating reprogramming methods. 
Derivation of clinical-grade retinal cells from hESC has been conducted in GMP facilities, and it is 
currently being used in phase I/II clinical trials as hESC-RPE suspension for Stargardt disease, 
geographic atrophy due to AMD and myopic atrophic macular degeneration (Clinical Trial: 
NCT01469832, NCT01345006, NCT01344993, NCT02122159) and hESC-RPE patch graft for wet 
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AMD (NCT01691261). There is only one human trial using iPSC-RPE, at the RIKEN Center for 
Developmental Biology (CDB), Japan. In the CDB trial, a monolayer of iPSC-RPE without substrate 
is used to treat neovascular AMD after a course of ranibizumab injections. One patient, in her 70s with 
wet AMD, has already received her own iPSC-RPE as a 1.3 × 3.0-mm cell patch at Kobe City Medical 
Center General Hospital in September [85]. This group has published data to support the in vitro and  
in vivo function of the iPSC-RPE in performing the visual cycle [68]. They also demonstrated 
suppression of the tumour-forming potential of iPSC by iPSC-RPE following subcutaneous 
transplantation in NOD/Shi-scid/IL-2Rγnull (NOG) mice. They postulated that pigment  
epithelium-derived factor secreted from iPSC-RPE or RPE of host tissue can cause apoptotic cell death 
of iPSC [86]. Following from this, the tumourigenicity of iPSC-RPE was also tested in nude, severe 
combined immune deficiency (SCID), non-obese diabetic (NOD)-SCID and NOG mice in the 
subretinal and subcutaneous location. They observed no tumour formation at 6–12 months following 
transplant [71]. Immune reaction to autologous iPSCs has not been studied, but Kamao et al. [70] 
demonstrated a lack of immune response after one year when nonhuman primate iPSC-RPE was 
transplanted as an autograft into the subretinal space. This study also confirmed no evidence of tumour 
formation following monkey iPSC-RPE autograft [70]. The RIKEN CDB has already enrolled patients 
with neovascular AMD for iPSC-RPE transplantation after the disease is stabilised with anti-VEGF 
therapy. Although the functionality of the graft seems to be well characterised, significant work still 
needs to be done in developing the optimal surgical instrumentation, technique and approach in 
resurfacing the RPE in the submacular space and patient selection for optimal visual and anatomical 
outcome. It is not known if iPSC-RPE survive, as multiple small patches of epithelial monolayer are 
superior to cell suspension and not inferior to a single large sheet of epithelial-substrate complex that 
can cover the entire macular region. The importance of restoring damaged Bruch’s membrane during 
iPSC-RPE replacement therapy in AMD cannot be underestimated, as this is considered as an 
important aspect of the pathophysiology of AMD [87]. 
In vitro genomic editing or mutation repair of harvested somatic cells, iPSCs or iPSC-derived 
retinal cells will provide patients with IRDs the opportunity to receive autologous cell therapy. For 
some IRDs that develop late-onset degeneration, genetic mutation correction in the patient-specific 
iPSCs may not be necessary [2]. This is relevant in the situation where the strategy is to transplant (1) 
iPSC-derived retinal supporting cells that are not affected by the mutation (e.g., RPE cells for ABCA4 
retinopathy); or (2) iPSC-derived retinal cells affected by the mutation, but it has delayed non-cell 
autonomous effects due to reduced trophic factor release (e.g., rod precursor cells for the cone 
preservation function through the release of rod-derived cone viability factor) [88]. For replacement of 
cone photoreceptor cells in cone dystrophy or RPE in RPE dystrophy, in vitro genomic editing may be 
required to allow iPSCs to differentiate into mature photoreceptors or the RPE phenotype and to 
ensure long-term survival of the autograft. Examples of in vitro gene therapy testing have been 
described in the previous section. Future strategies may include site-specific transcription  
activator-like effector nucleases (TALEN) or clustered regularly interspaced short palindromic repeats 
(CRISPR) based genome editing techniques, where the mutation is edited through a double-strand 
break (DSB) and off-target mutagenesis minimised by single-guide RNA. Following induction and 
subsequent homology-directed repair (HDR), the corrected gene will remain under the normal 
endogenous expression control elements. 
J. Clin. Med. 2014, 3 1534 
 
 
4. Conclusions 
Since the description of iPSCs in 2006, there has been an exponential increase in the translation of 
this technology towards understanding disease mechanisms and the discovery of therapeutics. The full 
potential is yet to be realised because of the complexity and variations in reprograming technology and 
retinal differentiation protocols. The relationship between the clinical disease phenotype and the 
molecular and cellular features of specific genetic variants in iPSC-derived retinal cells is still poorly 
understood. These issues will need to be resolved for iPSC-derived retinal tissue to become clinically 
relevant and useful in modelling retinal dysgenesis and degeneration. Standardisation and development 
of high throughput technology to interrogate specific retinal progeny derived from iPSCs will facilitate 
screening of genetic mutation and testing of pharmacologic and gene therapy in rare IRDs. Early data 
from several publications show that this may have a direct benefit to the patient [2,3,64,84]. iPSCs as a 
source of autologous cells are an attractive option, but there is a significant barrier to overcome for this 
to become scalable to treat large numbers of patients. However, progress in cell culture automation and 
refinements of reprogramming methods will undoubtedly facilitate the translation of iPSC-derived tissue 
into clinically applicable personalized cell therapy. Despite the mountain of challenge, the escalating 
costs of biologic therapy for treating neovascular and atrophic AMD and the suffering from irreversible 
childhood blindness due to IRDs, further ophthalmic translational research in iPSCs is worthy of the  
costly investment. 
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